Physician profile
Lauren Michelle Jufiar
NPI 1588461867
$4,091.76
in general payments reported to CMS, 2019-2025
24 companies · $4,092 in 2025
The $4,092 reported for 2025 was more than what 96% of Psychiatric/Mental Health (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $244).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $4,092.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,092.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,091.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $552.35 | 2025 | |
| Vanda Pharmaceuticals INC. | $479.67 | 2025 | Fanapt |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $462.17 | 2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $319.66 | 2025 | Spravato, Invega Sustenna |
| Abbvie INC. | $293.37 | 2025 | |
| Alkermes, INC. | $281.95 | 2025 | Aristada, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $255.01 | 2025 | Austedo Xr, Uzedy |
| Otsuka America Pharmaceutical, INC. | $234.13 | 2025 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| Noven Therapeutics, LLC | $169.64 | 2025 | Xelstrym |
| E.R. Squibb & Sons, L.L.C. | $158.15 | 2025 | Cobenfy |
| Braeburn INC. | $124.44 | 2025 | Brixadi |
| Supernus Pharmaceuticals, INC. | $113.97 | 2025 | Qelbree |
| Biogen, INC. | $110.32 | 2025 | Zurzuvae |
| Axsome Therapeutics, INC. | $96.88 | 2025 | Auvelity |
| Avadel Cns Pharmaceuticals, LLC | $93.02 | 2025 | Lumryz |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $61.53 | 2025 | Rexulti |
| Corium, LLC | $58.47 | 2025 | Azstarys |
| Collegium Pharmaceutical, INC. | $53.78 | 2025 | Jornay Pm |
| Idorsia Pharmaceuticals US INC | $46.05 | 2025 | Quviviq |
| Indivior INC. | $35.33 | 2025 | Sublocade |
| Luye Pharma (USA) Ltd. | $33.72 | 2025 | Erzofri Extended-Release |
| Bausch Health US, LLC | $24.69 | 2025 | Aplenzin, Wellbutrin |
| Takeda Pharmaceuticals U.S.A., INC. | $17.77 | 2025 | Trintellix |
| Tris Pharma INC | $15.69 | 2025 | Dyanavel Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Jufiar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.